Palivizumab (Systemic)

Brand Names : Synagis

Category

• Immunizing agent (passive)

Description

Palivizumab (pal-i-VI-zu-mab) belongs to a group of medicines known as immunizing agents. Palivizumab is used to prevent infection caused by respiratory syncytial virus (RSV). This medicine works by giving your body the antibodies it needs to protect it against RSV infection.

RSV infection can cause serious problems that affect the lungs, such as pneumonia and bronchitis, and in severe cases even can cause death. These problems are more likely to occur in infants and children younger than 6 months of age with chronic lung disease and breathing problems and in babies who were premature.

Palivizumab is used to prevent serious lower respiratory tract infection caused by the RSV.

Onset of RSV activity usually occurs in November and continues through April, but it may begin earlier or continue later in certain communities. A good way to help prevent RSV infection is to receive palivizumab before the start of the RSV season.

Palivizumab is to be administered only by or under the supervision of your doctor or other health care professional. It is available in the following dosage form:

Parenteral
• Injection (U.S.)

Brand Names

Some commonly used brand names are:

In the U.S. -

• Synagis